161 related articles for article (PubMed ID: 20211296)
1. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.
Teramoto T; Shimada K; Uchiyama S; Sugawara M; Goto Y; Yamada N; Oikawa S; Ando K; Ishizuka N; Yamazaki T; Yokoyama K; Murata M; Ikeda Y
Am Heart J; 2010 Mar; 159(3):361-369.e4. PubMed ID: 20211296
[TBL] [Abstract][Full Text] [Related]
2. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
Uchiyama S; Ishizuka N; Shimada K; Teramoto T; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Minematsu K; Matsumoto M; Ikeda Y;
Stroke; 2016 Jun; 47(6):1605-11. PubMed ID: 27165949
[TBL] [Abstract][Full Text] [Related]
5. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
[TBL] [Abstract][Full Text] [Related]
6. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
Ogawa H; Nakayama M; Morimoto T; Uemura S; Kanauchi M; Doi N; Jinnouchi H; Sugiyama S; Saito Y;
JAMA; 2008 Nov; 300(18):2134-41. PubMed ID: 18997198
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG; Amarenco P; Chamorro A; Fisher M; Ford I; Fox K; Hennerici MG; Mattle HP; Rothwell PM;
Cerebrovasc Dis; 2009; 27(5):509-18. PubMed ID: 19372653
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
9. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
Saito Y; Okada S; Ogawa H; Soejima H; Sakuma M; Nakayama M; Doi N; Jinnouchi H; Waki M; Masuda I; Morimoto T;
Circulation; 2017 Feb; 135(7):659-670. PubMed ID: 27881565
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis.
Farrant M; Easton JD; Adelman EE; Cucchiara BL; Barsan WG; Tillman HJ; Elm JJ; Kim AS; Lindblad AS; Palesch YY; Zhao W; Pauls K; Walsh KB; Martí-Fàbregas J; Bernstein RA; Johnston SC
JAMA Netw Open; 2019 Sep; 2(9):e1910769. PubMed ID: 31490536
[TBL] [Abstract][Full Text] [Related]
13. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
[TBL] [Abstract][Full Text] [Related]
14. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial.
Rodés-Cabau J; Masson JB; Welsh RC; Garcia Del Blanco B; Pelletier M; Webb JG; Al-Qoofi F; Généreux P; Maluenda G; Thoenes M; Paradis JM; Chamandi C; Serra V; Dumont E; Côté M
JACC Cardiovasc Interv; 2017 Jul; 10(13):1357-1365. PubMed ID: 28527771
[TBL] [Abstract][Full Text] [Related]
15. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Uchiyama S; Ikeda Y; Urano Y; Horie Y; Yamaguchi T
Cerebrovasc Dis; 2011; 31(6):601-13. PubMed ID: 21502757
[TBL] [Abstract][Full Text] [Related]
16. Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks.
Ando K; Shimada K; Yamazaki T; Uchiyama S; Uemura Y; Ishizuka N; Teramoto T; Oikawa S; Sugawara M; Murata M; Yokoyama K; Ikeda Y;
J Hypertens; 2019 Jun; 37(6):1301-1307. PubMed ID: 31022110
[TBL] [Abstract][Full Text] [Related]
17. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
Gaziano JM; Brotons C; Coppolecchia R; Cricelli C; Darius H; Gorelick PB; Howard G; Pearson TA; Rothwell PM; Ruilope LM; Tendera M; Tognoni G;
Lancet; 2018 Sep; 392(10152):1036-1046. PubMed ID: 30158069
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.
Jones WS; Mulder H; Wruck LM; Pencina MJ; Kripalani S; Muñoz D; Crenshaw DL; Effron MB; Re RN; Gupta K; Anderson RD; Pepine CJ; Handberg EM; Manning BR; Jain SK; Girotra S; Riley D; DeWalt DA; Whittle J; Goldberg YH; Roger VL; Hess R; Benziger CP; Farrehi P; Zhou L; Ford DE; Haynes K; VanWormer JJ; Knowlton KU; Kraschnewski JL; Polonsky TS; Fintel DJ; Ahmad FS; McClay JC; Campbell JR; Bell DS; Fonarow GC; Bradley SM; Paranjape A; Roe MT; Robertson HR; Curtis LH; Sharlow AG; Berdan LG; Hammill BG; Harris DF; Qualls LG; Marquis-Gravel G; Modrow MF; Marcus GM; Carton TW; Nauman E; Waitman LR; Kho AN; Shenkman EA; McTigue KM; Kaushal R; Masoudi FA; Antman EM; Davidson DR; Edgley K; Merritt JG; Brown LS; Zemon DN; McCormick TE; Alikhaani JD; Gregoire KC; Rothman RL; Harrington RA; Hernandez AF;
N Engl J Med; 2021 May; 384(21):1981-1990. PubMed ID: 33999548
[TBL] [Abstract][Full Text] [Related]
19. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Bhatt DL; Hirsch AT; Ringleb PA; Hacke W; Topol EJ
Am Heart J; 2000 Jul; 140(1):67-73. PubMed ID: 10874265
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low-dose aspirin in polycythemia vera.
Landolfi R; Marchioli R; Kutti J; Gisslinger H; Tognoni G; Patrono C; Barbui T;
N Engl J Med; 2004 Jan; 350(2):114-24. PubMed ID: 14711910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
